# Singapore Company Update Grand Venture Technology Ltd

# Bloomberg: GVTL SP | Reuters: GRAN.SI

Refer to important disclosures at the end of this report

DBS Group Research . Equity

# BUY


Last Traded Price (25 Feb 2025): SGD0.840 (STI: 3,927.75) Price Target 12-mth: SGD1.12 (34% upside) (Prev SGD1.04)

# Analysts

Amanda Tan amandatankh@dbs.com Lee Keng LING leekeng@dbs.com

# What's New

- FY24 earnings came in at SGD10.9mn (+96% y/y) on record revenue, above expectations
- Upbeat 1H25 revenue guidance of SGD90-96mn (+32%-41% y/y) reinforces growth narrative
- Higher utilisation and operating leverage to fuel earnings growth
- Maintain BUY with higher TP SGD1.12



Forecasts and Valuation				
FY Dec (SGDmn)	2023A	2024A	2025F	2026F
Revenue	111	160	194	221
EBITDA	23.0	29.2	39.4	45.6
Pre-tax Profit	6.08	9.03	16.1	21.1
Net Profit	5.54	10.9	14.5	18.6
Net Pft (Pre Ex.)	5.54	10.9	14.5	18.6
Net Pft Gth (Pre-ex) (%)	(58.4)	96.4	32.9	28.3
EPS (S cts)	1.63	3.21	4.27	5.47
EPS Pre Ex. (S cts)	1.63	3.21	4.27	5.47
EPS Gth Pre Ex (%)	(58)	96	33	28
Diluted EPS (S cts)	1.63	3.21	4.27	5.47
Net DPS (S cts)	0.10	0.30	0.64	0.82
BV Per Share (S cts)	35.0	39.1	42.7	47.4
PE (X)	51.4	26.2	19.7	15.4
PE Pre Ex. (X)	51.4	26.2	19.7	15.4
P/Cash Flow (X)	18.2	26.1	25.2	11.1
EV/EBITDA (X)	13.7	11.5	8.6	7.3
Net Div Yield (%)	0.1	0.4	0.8	1.0
P/Book Value (X)	2.4	2.1	2.0	1.8
Net Debt/Equity (X)	0.3	0.4	0.4	0.3
ROAE (%)	4.7	8.7	10.4	12.1
Earnings Rev (%):			7	8
Consensus EPS (S cts):			4.70	5.50
Other Broker Recs:		B: 2	S: 0	H: 0

Source of all data on this page: Company, DBS, Bloomberg

26 Feb 2025

# Doubling down on strong growth story

# **Investment Thesis:**

**High-growth company with a strong blue-chip customer base.** GVT has delivered strong revenue and earnings growth with 4-year CAGRs of 27% and 20%, respectively. GVT serves a blue-chip customer base – in the semiconductor back-end space, it serves four of the top six; in the analytical life sciences segment, it serves three of the top 10. The products supplied by GVT are manufactured to specific specifications, and the stringent process required to secure customers creates a strong competitive moat for the company.

Significant contributions from the front-end semiconductor space remain a crucial catalyst. GVT is involved in front end processes such

as etch, deposition, inspection, and metrology across technologies the likes of through-silicon via, atomic layer disposition, and high precision metrology. FY25 contributions from new front-end will grow meaningfully from a small base in FY24, followed by more significant contributions in FY26.

# Still a promising grand venture, as long-term semiconductor uptrend

**remains intact**. Notwithstanding cyclicality, the semiconductor industry is poised for growth, owing to the push towards digitalisation. McKinsey projects that the semiconductor industry will become a trillion-dollar market by 2030. The long-term semiconductor outlook looks bright, which should benefit GVT, as more than half of its revenue comes from the semiconductor segment.

# Maintain BUY with higher TP SGD1.12 (vs. SGD1.04 previously). Our target PE peg is unchanged, with TP based on 21x FY26F earnings (close to historical mean) to account for more meaningful volume production for new FE customers. We raised FY25/26F revenue by 11%/6% due to stronger than expected contributions from the semiconductor segment. Accordingly, we lifted our FY25/26F earnings by 7% and 8%, respectively, driven by higher topline growth. However, this is slightly tempered by higher assumed finance costs from increased leverage and toned-down gross margin assumptions due to higher costs related to onboarding new customers.

# Key Risks

Delay in front-end expansion, semiconductor downcycles

# At A Glance

339
285/212
26.7
15.4
8.8
49.1
0.29
are





# WHAT'S NEW

#### Doubling down on strong growth story

Strong finish to FY24 with full year revenue and earnings

outperforming our estimates by 7-14%. FY24 earnings came in at SGD10.9mn (+96.4% y/y), on record revenue at SGD159.5mn (+43.3% y/y). Revenue exceeded the top end of guidance of SGD154.3mn due to stronger performance across all three segments. Revenue from the semiconductor segment soared 64.9% y/y to SGD87.8mn (55% of revenue) on strong HBM tester demand and commencement of front-end mass production. The life sciences segment grew 11.3% y/y to SGD22.9mn as supply chain shifts to South-East Asia drove wallet share gains from new projects with key customers. The EAMO (electronics, aerospace, medical, and others) segment also surged to SGD48.8mn (+30.3% y/y) on contributions from the ACP acquisition and robust demand in aerospace and medical segments.

Gross margins compressed 0.5ppts to 24.5% on higher expenses incurred in onboarding new customers and a one-off SGD0.7mn provision for inventory and write downs. EBITDA margin also declined by 1.9ppts to 18.1% on lower gross margins and non-recurring expenses of SGD1.8mn in professional fees due to a planned secondary listing, M&A expenses, and inventory write downs. Net profit margin came in at 6.8% (+1.8 ppts) benefitting from deferred income tax credits of SGD2.0mn, resulting in profit after tax of SGD10.9mn (+96.4% y/y), above our expectations.

# Upbeat 1H25 revenue guidance of SGD90-96mn (+31.7-40.5%

y/y) reinforces growth narrative. FY25F topline forecast was above our expectations with annualised revenue of SGD186mn based on 1H25 guidance exceeding our FY25F revenue estimate by 6%. Management's optimistic outlook is on the back of (i) higher semiconductor demand anticipated from AI and complexity-driven equipment sales involving technologies the likes of thermal compression bonding, through-silicon via, and hybrid bonding (ii) stronger demand for aircraft components driven by resilient global air travel, and (iii) healthy life sciences demand supported by the industry's resilience across market cycles.

**Structural tailwinds poised to drive sustained growth**. Long term secular tailwinds are intact with semiconductor equipment forecast to grow at an 8.9% CAGR between 2023-2028. Packaging and testing equipment demand will also be robust,

attributable to rising demand for high bandwidth memory and advanced packaging, driving derived demand for GVT's high precision components. Further, GVT remains well diversified with its exposure to life sciences, and the EAMO segment. Those segments will also be supported by a 10% CAGR in the global mass spectrometry market between 2023-2028 and a doubling of aircraft fleet over the course of the next 20 years.

#### Higher utilisation and operating leverage to fuel earnings growth.

Given GVT's strong positioning to capitalise on the structural trends outlined above, we forecast revenue and earnings growth CAGRs of 18% and 31%, respectively, between FY24 and FY26. We believe that improved utilisation and higher operating leverage should lead to an expansion of the net profit margin to 7.5%/8.4% in FY25/26, up from 6.8% in FY24

#### Maintain BUY with higher TP SGD1.12 (vs SGD1.04 previously).

Our target PE peg remains unchanged, and our TP is based on 21x FY26F earnings (close to the historical mean) to account for more meaningful volume production for new FE customers. We have raised our FY25/26F revenue by 11%/6% due to stronger than expected contributions from the semiconductor segment. Accordingly, we lifted our FY25/26F earnings by 7% and 8%, respectively, driven by higher topline growth. However, this is slightly tempered by higher assumed finance costs from increased leverage and toned-down gross margin assumptions due to higher costs related to onboarding new customers.

#### **Company Background**

Grand Venture Technology Limited was established in 2012 and is a manufacturing solutions and services provider for the semiconductor, life sciences, electronics, medical, and industrial automation industries. Its manufacturing plants are in Singapore, Malaysia, and China. Its customer base includes established blue-chip companies in the semiconductor back-end and analytical life sciences industries.

#### Interim Income Statement (SGDmn)

FY Dec	2H2023	1H2024	2H2024	% chg y/y	% chg h/h
Revenue	57	68	91	58.8	33.5
Cost of Goods Sold	(43)	(50)	(70)	62.7	39.6
Gross Profit	14	18	21	47.0	16.7
Other Oper. (Exp)/Inc	(11)	(12)	(15)	33.8	27.1
Operating Profit	3	6	6	93.1	(2.6)
Other Non Opg (Exp)/Inc	0	0	0	-	-
Associates & JV Inc	0	0	0	-	-
Net Interest (Exp)/Inc	(1)	(1)	(2)	(64.2)	(27.6)
Exceptional Gain/(Loss)	0	0	0	-	-
Pre-tax Profit	2	5	4	109.8	(12.1)
Тах	0	0	2	nm	nm
Minority Interest	0	0	0	-	-
Net Profit	2	4	7	207.4	52.8
Net profit bef Except.	2	4	7	207.4	52.8
EBITDA	3	6	6	93.1	(2.6)
Margins (%)					
Gross Margins	24.9	26.4	23.0		
Opg Profit Margins	5.5	9.2	6.7		
Net Profit Margins	3.7	6.3	7.2		

Source of all data: Company, DBS

# Historical PE and PB band



Source: Bloomberg, DBS estimates



Source: Bloomberg, DBS estimates



# Income Statement (SGDmn)

Income Statement (SGDmn)					
FY Dec	2022A	2023A	2024A	2025F	2026F
Revenue	131	111	160	194	221
Cost of Goods Sold	(95.3)	(83.5)	(120)	(142)	(160)
Gross Profit	35.8	27.8	39.0	51.9	61.0
Other Opng (Exp)/Inc	(19.6)	(19.4)	(26.6)	(31.8)	(36.1)
Operating Profit	16.2	8.42	12.4	20.1	24.9
Other Non Opg (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Associates & JV Inc	0.0	0.0	0.0	0.0	0.0
Net Interest (Exp)/Inc	(2.4)	(2.3)	(3.4)	(4.0)	(3.8)
Exceptional Gain/(Loss)	0.0	0.0	0.0	0.0	0.0
Pre-tax Profit	13.9	6.08	9.03	16.1	21.1
Тах	(0.6)	(0.5)	1.86	(1.6)	(2.5)
Minority Interest	0.0	0.0	0.0	0.0	0.0
Preference Dividend	0.0	0.0	0.0	0.0	0.0
Net Profit	13.3	5.54	10.9	14.5	18.6
Net Profit before Except.	13.3	5.54	10.9	14.5	18.6
EBITDA	30.2	23.0	29.2	39.4	45.6
Growth					
Revenue Gth (%)	12.8	(15.1)	43.3	21.5	14.2
EBITDA Gth (%)	(4.0)	(23.8)	26.9	34.8	15.8
Opg Profit Gth (%)	(28.2)	(48.1)	47.7	61.6	23.8
Net Profit Gth (Pre-ex) (%)	(24.1)	(58.4)	96.4	32.9	28.3
Margins & Ratio					
Gross Margins (%)	27.3	25.0	24.5	26.8	27.6
Opg Profit Margin (%)	12.4	7.6	7.8	10.4	11.2
Net Profit Margin (%)	10.2	5.0	6.8	7.5	8.4
ROAE (%)	12.0	4.7	8.7	10.4	12.1
ROA (%)	6.9	2.7	4.7	5.3	6.5
ROCE (%)	6.6	1.8	3.8	4.7	6.2
Div Payout Ratio (%)	15.3	6.1	9.3	15.0	15.0
Net Interest Cover (x)	6.9	3.6	3.6	5.0	6.6

Source: Company, DBS

# Interim Income Statement (SGDmn)

FY Dec	2H2022	1H2023	2H2023	1H2024	2H2024
Davage	64.0	52.0		(0.2	01.2
Revenue	64.0	53.9	57.4	68.3	91.2
Cost of Goods Sold	(46.3)	(40.3)	(43.1)	(50.3)	(70.2)
Gross Profit	17.7	13.5	14.3	18.0	21.0
Other Oper. (Exp)/Inc	(11.0)	(8.3)	(11.1)	(11.7)	(14.9)
Operating Profit	6.69	5.25	3.18	6.30	6.14
Other Non Opg (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Associates & JV Inc	0.0	0.0	0.0	0.0	0.0
Net Interest (Exp)/Inc	(1.2)	(1.2)	(1.2)	(1.5)	(1.9)
Exceptional Gain/(Loss)	0.0	0.0	0.0	0.0	0.0
Pre-tax Profit	5.48	4.06	2.01	4.80	4.22
Тах	0.72	(0.7)	0.13	(0.5)	2.36
Minority Interest	0.0	0.0	0.0	0.0	0.0
 Net Profit	6.19	3.40	2.14	4.31	6.58
Net profit bef Except.	6.19	3.40	2.14	4.31	6.58
EBITDA	6.69	5.25	3.18	6.30	6.14
Growth					
Revenue Gth (%)	(4.5)	(15.9)	6.6	18.9	33.5
EBITDA Gth (%)	(29.9)	(21.6)	(39.4)	98.3	(2.6)
Opg Profit Gth (%)	(29.9)	(21.6)	(39.4)	98.3	(2.6)
Net Profit Gth (%)	(13.2)	(45.1)	(37.1)	101.2	52.8
Margins	( ) = ( _ )	()	()		
Gross Margins (%)	27.7	25.1	24.9	26.4	23.0
Opg Profit Margins (%)	10.4	9.7	5.5	9.2	6.7
Net Profit Margins (%)	9.7	6.3	3.7	6.3	7.2
	2.1	0.0	5.7	0.0	· .∠

# Balance Sheet (SGDmn)

FY Dec	2022A	2023A	2024A	2025F	2026F
	20227	ZUZJA	20247	ZUZJF	20205
Net Fixed Assets	84.4	83.5	105	101	95.4
Invts in Associates & JVs	0.0	0.0	0.0	0.0	0.0
Other LT Assets	10.9	10.2	11.6	11.2	10.8
Cash	23.1	19.1	22.3	16.4	24.4
ST Invtestment	0.0	0.0	0.0	0.0	0.0
Inventory	50.6	56.7	71.0	85.1	96.2
Debtors	32.0	30.6	50.2	58.2	66.4
Net Intangibles Assets	10.2	9.46	9.90	9.49	9.07
Other Current Assets	3.04	3.08	5.02	5.02	5.02
Total Assets	204	203	265	277	298
ST Debt	18.7	20.8	29.7	29.7	29.7
Creditor	23.2	26.2	44.5	44.2	49.9
Other Current Liab	2.73	2.62	3.72	3.72	3.72
LT Debt	32.3	28.2	42.2	42.2	42.2
Other LT Liabilities	9.22	6.91	11.9	11.9	11.9
Shareholder's Equity	118	119	133	145	161
Minority Interests	0.0	0.0	0.0	0.0	0.0
Total Cap. & Liab.	204	203	265	277	298
Non Cash W/kg Capital	59.8	61.6	78.0	100	114
Non-Cash Wkg. Capital Net Cash/(Debt)	(27.8)	(29.9)	(49.6)	(55.5)	(47.5)
Debtors Turn (avg days)	(27.8) 86.3	(29.9) 102.7	92.5	102.0	(47.3) 102.7
Creditors Turn (avg days)	108.3	130.9	124.4	131.9	123.0
Inventory Turn (avg days)	205.5	284.4	224.6	232.3	237.1
Asset Turnover (x)	203.3	0.5	0.7	0.7	0.8
Current Ratio (x)	2.4	2.2	1.9	2.1	2.3
Quick Ratio (x)	1.2	1.0	0.9	1.0	2.5
Net Debt/Equity (X)	0.2	0.3	0.9	0.4	0.3
Net Debt/Equity (x)	0.2	0.3	0.4	0.4	0.3
Capex to Debt (%)	19.1	20.9	14.5	20.9	20.9
	1.1	20.5	14.5	20.5	20.9

Source: Company, DBS




#### Cash Flow Statement (SGDmn)

mn)				
2022A	2023A	2024A	2025F	2026F
13.9	6.08	9.03	16.1	21.1
				20.7
				(2.5)
	• •	• •	, ,	0.0
				(13.5)
. ,	• •	• •	, ,	0.0
13.4	15.7	10.9	11.3	25.7
(9.7)	(10.2)	(10.4)	(15.0)	(15.0)
0.0	0.0	0.0	0.0	0.0
(6.9)	0.0	0.0	0.0	0.0
0.0	0.0	0.0	0.0	0.0
0.82	0.50	(15.2)	0.0	0.0
(15.8)	(9.7)	(25.6)	(15.0)	(15.0)
(2.7)	(1.0)	(0.3)	(2.2)	(2.8)
(7.5)	1.48	14.2	0.0	0.0
0.0	0.0	0.0	0.0	0.0
· · /	(10.0)	1.06	0.0	0.0
	(9.5)	14.9	(2.2)	(2.8)
· ,	· · ·			0.0
. ,	• •		, ,	7.95
				11.6
1.09	1.60	0.14	(1.1)	3.16
	2022A 13.9 14.0 (1.3) 0.0 (11.5) (1.6) 13.4 (9.7) 0.0 (6.9) 0.0 0.82 (15.8) (2.7) (7.5)	2022A         2023A           13.9         6.08           14.0         14.6           (1.3)         (0.7)           0.0         0.0           (11.5)         (2.0)           (11.5)         (2.0)           (11.5)         (2.0)           (1.6)         (2.3)           13.4         15.7           (9.7)         (10.2)           0.0         0.0           (6.9)         0.0           0.0         0.0           0.0         0.0           0.27)         (1.0)           (7.5)         1.48           0.0         0.0           (9.7)         (10.0)           (7.5)         1.48           0.0         0.0           (9.7)         (10.0)           (19.9)         (9.5)           (0.7)         (0.4)           (23.0)         (4.0)           7.34         5.20	2022A         2023A         2024A           13.9         6.08         9.03           14.0         14.6         16.8           (1.3)         (0.7)         (0.6)           0.0         0.0         0.0           (11.5)         (2.0)         (16.5)           (1.6)         (2.3)         2.21           13.4         15.7         10.9           (9.7)         (10.2)         (10.4)           0.0         0.0         0.0           (6.9)         0.0         0.0           0.0         0.0         0.0           0.0         0.0         0.0           0.27)         (10.2)         (10.4)           0.0         0.0         0.0           0.0         0.0         0.0           0.0         0.0         0.0           0.27)         (1.0)         0.0           (2.7)         1.48         14.2           0.0         0.0         0.0           (2.7)         1.48         14.2           0.0         0.0         0.0           (9.7)         (10.0)         1.06           (19.9)         (9.5)         14.9	2022A         2023A         2024A         2025F           13.9         6.08         9.03         16.1           14.0         14.6         16.8         19.3           (1.3)         (0.7)         (0.6)         (1.6)           0.0         0.0         0.0         0.0           (1.1.5)         (2.0)         (16.5)         (22.4)           (1.6)         (2.3)         2.21         0.0           13.4         15.7         10.9         11.3           (9.7)         (10.2)         (10.4)         (15.0)           0.0         0.0         0.0         0.0           0.6         0.0         0.0         0.0           0.6         0.0         0.0         0.0           0.0         0.0         0.0         0.0           0.0         0.0         0.0         0.0           0.82         0.50         (15.2)         0.0           0.82         0.50         (15.2)         0.0           (2.7)         1.0         (0.3)         (2.2)           (7.5)         1.48         14.2         0.0           0.0         0.0         0.0         0.0         0.0

Source: Company, DBS

# Target Price & Ratings 12-mth History



S.No.	Date of Report	Closing Price	12-mth Target Price	Rating
1:	27 Feb 24	0.49	0.58	BUY
2:	14 Aug 24	0.55	0.70	BUY
3:	06 Jan 25	0.86	1.04	BUY

Source: DBS Analysts: Amanda Tan Lee Keng LING

DBS Group Research recommendations are based on an Absolute Total Return\* Rating system, defined as follows: STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame) BUY (>15% total return over the next 12 months for small caps, >10% for large caps) HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps) FULLY VALUED (negative total return, i.e., > -10% over the next 12 months) SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

\*Share price appreciation + dividends

Completed Date: 26 Feb 2025 07:48:21 (SGT) Dissemination Date: 26 Feb 2025 07:51:49 (SGT)

Sources for all charts and tables are DBS unless otherwise specified.

# GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd. This report is solely intended for the clients of DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "**DBS Group**") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

# ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function of the DBS Group.

# COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), DBSVUSA, or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 31 Jan 2025.

#### Compensation for investment banking services:

2. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

#### Disclosure of previous investment recommendation produced:

3. DBS Bank Ltd, DBS HK, DBSVS, DBSVUSA, their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed on page 1 of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

<sup>&</sup>lt;sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>&</sup>lt;sup>2</sup> Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



# RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.
	DBS Bank Ltd, DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.
	Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.
Hong Kong	This report has been prepared by a personnel of DBS Bank Ltd, who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited ("DBS HK"), a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.
	For any query regarding the materials herein, please contact Dennis Lam (Reg No. AH8290) at dbsvhk@dbs.com
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services for the subject companies.
	And
	Wong Ming Tek, Executive Director, ADBSR
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6878 8888 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd. For any query regarding the materials herein, please contact Chanpen Sirithanarattanakul at research@dbs.com



United	This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore.
Kingdom	This report is disseminated in the United Kingdom by DBS Bank Ltd, London Branch ("DBS UK"). DBS UK is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority.
	In respect of the United Kingdom, this report is solely intended for the clients of DBS UK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS UK, This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This communication is provided to you as a Professional Client or Market Counterparty as defined in the DFSA Rulebook Conduct of Business Module (the "COB Module"), and should not be relied upon or acted on by any person which does not meet the criteria to be classified as a Professional Client or Market Counterparty under the DFSA rules.
	This communication is from the branch of DBS Bank Ltd operating in the Dubai International Financial Centre (the "DIFC") under the trading name "DBS Bank Ltd. (DIFC Branch)" ("DBS DIFC"), registered with the DIFC Registrar of Companies under number 156 and having its registered office at units 608 - 610, 6th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates.
	DBS DIFC is regulated by the Dubai Financial Services Authority (the "DFSA") with a DFSA reference number F000164. For more information on DBS DIFC and its affiliates, please see <a "offer="" (difc="" 12="" 19(2)="" 2010).<="" 2012)="" a="" an="" article="" as="" collective="" defined="" fund"="" href="http://www.dbs.com/ae/our&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;&lt;/th&gt;&lt;th&gt;Where this communication contains a research report, this research report is prepared by the entity referred to therein, which may be DBS Bank Ltd or a third party, and is provided to you by DBS DIFC. The research report has not been reviewed or authorised by the DFSA. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBS DIFC.&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;&lt;/th&gt;&lt;th&gt;Unless otherwise indicated, this communication does not constitute an " investment="" law="" markets="" no.1="" no.2="" of="" offer="" or="" public"="" securities="" th="" the="" to="" under="" unit=""></a>
	The DFSA has no responsibility for reviewing or verifying this communication or any associated documents in connection with this investment and it is not subject to any form of regulation or approval by the DFSA. Accordingly, the DFSA has not approved this communication or any other associated documents in connection with this investment nor taken any steps to verify the information set out in this communication or any associated documents to which the communication relates and, in respect of any Islamic investments (or other investments identified to be Shari'a compliant), neither we nor the DFSA has determined whether they are Shari'a compliant in any way.
	Any investments which this communication relates to may be illiquid and/or subject to restrictions on their resale. Prospective purchasers should conduct their own due diligence on any investments. If you do not understand the contents of this document you should consult an authorised financial adviser.
United States	This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.



Other jurisdictions In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such iurisdictions.

# DBS Regional Research Offices

# HONG KONG

DBS Bank (Hong Kong) Ltd

Contact: Dennis Lam 13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: 852 3668 4181 Fax: 852 2521 1812 e-mail: dbsvhk@dbs.com

# INDONESIA

#### PT DBS Vickers Sekuritas (Indonesia)

Contact: William Simadiputra DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943 e-mail: indonesiaresearch@dbs.com

#### SINGAPORE DBS Bank Ltd

Contact: Andy Sim 12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982 Tel: 65 6878 8888 e-mail: groupresearch@dbs.com Company Regn. No. 196800306E

# THAILAND

DBS Vickers Securities (Thailand) Co Ltd Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269 e-mail: research@dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission, Thailand